Biodexa Moves to 1-for-8 Reverse ADS Split, Effective October 26
Summary
Biodexa announced a 1-for-8 reverse ADS split effective on or about October 26, 2026, requiring ADS holders to exchange eight old ADSs for one new ADS. The move is designed to lift the ADS price and maintain NASDAQ listing compliance.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
Effective on or about October 26, 2026, the ADS ratio will shift from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares. ADS holders must exchange 8 old ADSs for 1 new ADS.
-
Mandatory Exchange and CUSIP Change
The exchange is mandatory. New CUSIP is 59564R864; old CUSIP is 59564R872. No fractional ADSs will be allocated; aggregate fractions will be sold and net proceeds distributed to entitled holders.
-
Listing Compliance Motivation
The reverse split is intended to raise the ADS price to maintain NASDAQ Capital Market listing compliance, following a going concern warning and a cash balance of £3.23 million as of June 30, 2026.
-
No Change to Ordinary Shares
The underlying ordinary shares are not affected by the ratio change. The company's market capitalization and total equity value remain unchanged.
Analysis · BDRX · Life Sciences
To maintain NASDAQ listing compliance, Biodexa is adjusting its ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares—equivalent to a 1-for-8 reverse ADS split. ADS holders must surrender their old ADSs to receive one new ADS for every eight old ADSs. This mandatory corporate action comes amid a going concern warning and a cash balance of only £3.23 million as of June 30, 2026. While the reverse split does not alter the underlying ordinary shares or the company's market capitalization, it will reduce the number of ADSs outstanding and mechanically raise the per-ADS price.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.5% of the 1962 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.